|
Market Closed -
Euronext Paris
11:55:00 2026-11-04 EST
|
5-day change | 1st Jan Change | ||
| 9.200 EUR | -0.55% |
|
+4.55% | -45.40% |
| 10-19 | Sensorion Announces Appointment of Peter Weber as Chief Medical Officer, Effective November 2, 2026 | CI |
| 10-19 | Sensorion rallies after appointment of chief medical officer |  |
| Market Cap | 94.81M 106M 86.94M 79.01M 149M 10.05B 152M 1.04B 417M 5.32B 399M 391M 16.86B | P/E 2026 * |
-2.75x | P/E 2027 * | -4.11x |
|---|---|---|---|---|---|
| Enterprise Value | 20.81M 23.35M 19.08M 17.34M 32.6M 2.21B 33.34M 228M 91.42M 1.17B 87.64M 85.76M 3.7B | EV / Sales 2026 * |
4.46x | EV / Sales 2027 * | 1.24x |
| Free-Float |
65.24% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Euronext Paris
| ALSEN | Real-time | |
CBOE
| Real-time | ||
|
Börse Stuttgart
| RFM | Delayed | |
|
Börse Stuttgart
| RFM | Delayed | |
|
CBOE
| Real-time | ||
|
Deutsche Boerse AG
| RFM | Delayed | |
|
Boerse Muenchen
| RFM | Real-time | |
|
CBOE
| Real-time | ||
|
Boerse Muenchen
| RFM | Real-time | |
|
CBOE
| Real-time | ||
|
Tradegate
| RFM | Real-time |
| 1 day | -0.55% | ||
| 1 week | +4.55% | ||
| Current month | +6.48% | ||
| 1 month | +39.18% | ||
| 3 months | -33.81% | ||
| 6 months | -54.46% | ||
| Current year | -45.40% |
| 1 week | 8.5 |  | 9.49 |
| 1 month | 5.25 | | 10.26 |
| Current year | 5.25 | | 40.4 |
| 1 year | 5.25 | | 40.4 |
| 3 years | 5.25 | | 52 |
| 5 years | 5.25 | | 114.5 |
| 10 years | 5.25 | | 387 |
| Manager | Title | Age | Since |
|---|---|---|---|
Frédéric Chéreau
CEO | Chief Executive Officer | 59 | 2026-05-31 |
Louis Arcudi
DFI | Director of Finance/CFO | 65 | 2026-10-06 |
Bernd Schmidt
CTO | Chief Tech/Sci/R&D Officer | - | 2023-12-10 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | - | 2015-03-08 | |
Julien Miara
BRD | Director/Board Member | 43 | - |
Khalil Barrage
CHM | Chairman | 61 | 2023-03-29 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 2/6/26 | Redmile Biopharma Investments III LP
| Buy | Company | 18,928,571 | 6.2956% | |
| 1/31/26 | Sofinnova Partners SAS
| Buy | Company | 10,714,285 | 3.5636% | |
| 4/18/24 | Redmile Biopharma Investments III LP
| Buy | Company | 2,781,914 | 1.0091% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.55% | +4.55% | -47.43% | -68.81% | 107M | |
| +10.00% | +5.18% | +54.35% | +71.20% | 60.57B | |
| +1.44% | +4.06% | +22.70% | +101.03% | 55.51B | |
| +3.32% | +4.11% | +14.82% | +75.04% | 55.22B | |
| +0.46% | -2.86% | +23.34% | +33.77% | 43.27B | |
| +6.42% | +3.20% | +21.14% | +105.56% | 40.36B | |
| +2.82% | +7.24% | +236.59% | +801.17% | 41.63B | |
| -3.79% | +19.39% | +91.90% | +77.13% | 33.29B | |
| +5.32% | +6.04% | +20.27% | +52.98% | 32.27B | |
| +5.32% | +15.84% | -40.93% | +342.66% | 22.91B | |
| Average | +3.08% | +5.03% | +39.68% | +159.17% | 38.51B | |
| Weighted average by Cap. | +3.72% | +4.06% | +51.55% | +169.45% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 4.66M 5.23M 4.28M 3.89M 7.31M 495M 7.47M 51.11M 20.49M 262M 19.64M 19.22M 829M | 15.92M 17.87M 14.6M 13.27M 24.94M 1.69B 25.51M 174M 69.95M 894M 67.06M 65.63M 2.83B |
| Net income | -36M -40.4M -33.01M -30M -56.4M -3.82B -57.69M -395M -158M -2.02B -152M -148M -6.4B | -28.79M -32.3M -26.4M -23.99M -45.1M -3.05B -46.13M -316M -126M -1.62B -121M -119M -5.12B |
| Net Debt | -74M -83.04M -67.86M -61.67M -116M -7.85B -119M -811M -325M -4.15B -312M -305M -13.16B | -75M -84.17M -68.78M -62.51M -118M -7.95B -120M -822M -330M -4.21B -316M -309M -13.34B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-11-04 | €9.200 | -0.55% | 9,287 |
| 26-11-03 | €9.251 | +0.98% | 8,125 |
| 26-11-02 | €9.161 | +6.03% | 11,119 |
| 26-10-30 | €8.640 | -2.92% | 5,334 |
| 26-10-29 | €8.900 | +1.14% | 13,336 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ALSEN Stock
Select your edition
All financial news and data tailored to specific country editions
